BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment

Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study

(2016) Adrian H Heald et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Metformin as firstline treatment for type 2 diabetes: are we sure?

(2016) Rémy Boussageon et al.   BMJ-British Medical Journal

Primary care management of patients after weight loss surgery

(2016) Michael Moore et al.   BMJ-British Medical Journal

Drugs for smoking cessation

(2016) Jamie Hartmann-Boyce et al.   BMJ-British Medical Journal

Metformin as firstline treatment for type 2 diabetes: are we sure?

(2016) Rémy Boussageon et al.   BMJ-British Medical Journal

Primary care management of patients after weight loss surgery

(2016) Michael Moore et al.   BMJ-British Medical Journal

Drugs for smoking cessation

(2016) Jamie Hartmann-Boyce et al.   BMJ-British Medical Journal

Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management

(2015) P. Manu et al.   ACTA PSYCHIATRICA SCANDINAVICA

Pragmatic Replication Trial of Health Promotion Coaching for Obesity in Serious Mental Illness and Maintenance of Outcomes

(2015) Stephen J. Bartels et al.   AMERICAN JOURNAL OF PSYCHIATRY

The STRIDE Weight Loss and Lifestyle Intervention for Individuals Taking Antipsychotic Medications: A Randomized Trial

(2015) Carla A. Green et al.   AMERICAN JOURNAL OF PSYCHIATRY

The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes

(2015) Tamara S. Hannon et al.   Annals of the New York Academy of Sciences

Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis

(2015) Jackie Curtis et al.   Early Intervention in Psychiatry

Long-Acting Injectable vs Oral Risperidone for Schizophrenia and Co-Occurring Alcohol Use Disorder

(2015) Alan I. Green et al.   JOURNAL OF CLINICAL PSYCHIATRY

Importance of Early Weight Changes to Predict Long-Term Weight Gain During Psychotropic Drug Treatment

(2015) Frederik Vandenberghe et al.   JOURNAL OF CLINICAL PSYCHIATRY

Cardiovascular risks and benefits of moderate and heavy alcohol consumption

(2015) Joaquim Fernández-Solà   Nature Reviews Cardiology

Bariatric surgery: a viable treatment option for patients with severe mental illness

(2015) Sarah R. Shelby et al.   Surgery for Obesity and Related Diseases

Patients with psychiatric comorbidity can safely undergo bariatric surgery with equivalent success

(2015) Hans F. Fuchs et al.   SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES

Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK

(2015) T R E Barnes et al.   BMJ Open

Smoking cessation and reduction in people with chronic mental illness

(2015) Jennifer W Tidey et al.   BMJ-British Medical Journal

All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts

(2015) C. S. Knott et al.   BMJ-British Medical Journal

Smoking cessation and reduction in people with chronic mental illness

(2015) Jennifer W Tidey et al.   BMJ-British Medical Journal

All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts

(2015) C. S. Knott et al.   BMJ-British Medical Journal

Premature Mortality Among Adults With Schizophrenia in the United States

(2015) Mark Olfson et al.   JAMA Psychiatry

Cardiovascular Risk Prediction Models for People With Severe Mental Illness

(2015) David P. J. Osborn et al.   JAMA Psychiatry

Metabolic syndrome in people with schizophrenia: a review

(2015) MARC DE HERT et al.   World Psychiatry

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care

(2015) MARC DE HERT et al.   World Psychiatry

Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial

(2014) Francisco Romo-Nava et al.   BIPOLAR DISORDERS

Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study

(2014) Mike J. Crawford et al.   BRITISH JOURNAL OF PSYCHIATRY

Smoking and Long-Term Risk of Type 2 Diabetes: The EPIC-InterAct Study in European Populations

(2014)   DIABETES CARE

Quality of prescribing for schizophrenia: Evidence from a national audit in England and Wales

(2014) Maxine X. Patel et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

An Exploratory Randomized Controlled Study of a Healthy Living Intervention in Early Intervention Services for Psychosis

(2014) Karina Lovell et al.   JOURNAL OF CLINICAL PSYCHIATRY

Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study

(2014) Amirhossein Modabbernia et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

(2014) Rury R Holman et al.   LANCET

Diabetes mellitus and severe mental illness: mechanisms and clinical implications

(2014) Richard I. G. Holt et al.   Nature Reviews Endocrinology

Continuing Weight-Loss Effect after Topiramate Discontinuation in Obese Persons with Schizophrenia: a Pilot Open-Label Study

(2014) C.-S. Liang et al.   PHARMACOPSYCHIATRY

The Effects of Lifestyle Interventions on (Long-Term) Weight Management, Cardiometabolic Risk and Depressive Symptoms in People with Psychotic Disorders: A Meta-Analysis

(2014) Jojanneke Bruins et al.   PLoS One

Views of Young People in Early Intervention Services for First-Episode Psychosis in England

(2014) Helen Lester et al.   PSYCHIATRIC SERVICES

Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis

(2014) Y. Mizuno et al.   SCHIZOPHRENIA BULLETIN

Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders

(2014) Christoph U. Correll et al.   JAMA Psychiatry

Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder

(2013) L. Fredrik Jarskog et al.   AMERICAN JOURNAL OF PSYCHIATRY

Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes

(2013) Pelle L. Ishøy et al.   AMERICAN JOURNAL OF PSYCHIATRY

The effect of bariatric surgery on psychiatric course among patients with bipolar disorder

(2013) Ameena T Ahmed et al.   BIPOLAR DISORDERS

P.6.f.003 Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes

(2013) G. Minutolo et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone

(2013) Siti Norsyuhada Roffeei et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo

(2013) Stephen M. Stahl et al.   JOURNAL OF CLINICAL PSYCHIATRY

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

(2013) Stefan Leucht et al.   LANCET

A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness

(2013) Gail L. Daumit et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinically Significant Improved Fitness and Weight Loss Among Overweight Persons With Serious Mental Illness

(2013) Stephen J. Bartels et al.   PSYCHIATRIC SERVICES

The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial

(2013) Ahmad Ghanizadeh et al.   SCHIZOPHRENIA RESEARCH

A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls

(2013) Davy Vancampfort et al.   World Psychiatry

The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers

(2013) D. Lawrence et al.   BMJ-British Medical Journal

Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth

(2013) William V. Bobo et al.   JAMA Psychiatry

Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia

(2012) X. Fan et al.   ACTA PSYCHIATRICA SCANDINAVICA

Metformin for Treatment of Antipsychotic-Induced Amenorrhea and Weight Gain in Women With First-Episode Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Study

(2012) Ren-Rong Wu et al.   AMERICAN JOURNAL OF PSYCHIATRY

Zonisamide for Weight Reduction in Obese Adults

(2012) Kishore M. Gadde et al.   ARCHIVES OF INTERNAL MEDICINE

Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study

(2012)   DIABETES CARE

The heart of the matter: cardiometabolic care in youth with psychosis

(2012) Jackie Curtis et al.   Early Intervention in Psychiatry

Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial

(2012) W. Wolfgang Fleischhacker et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Comparison of Long-Term (At Least 24 Weeks) Weight Gain and Metabolic Changes Between Adolescents and Adults Treated with Olanzapine

(2012) Ludmila A. Kryzhanovskaya et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Tobacco Use Before, At, and After First-Episode Psychosis

(2012) Nicholas Myles et al.   JOURNAL OF CLINICAL PSYCHIATRY

Effect of Topiramate on Weight Gain in Patients Receiving Atypical Antipsychotic Agents

(2012) Shamail Mahmood et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP

(2012) AR Lingford-Hughes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The Role of Primary Care in Service Provision for People with Severe Mental Illness in the United Kingdom

(2012) Siobhan Reilly et al.   PLoS One

Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine–betahistine combination

(2012) Michael Poyurovsky et al.   PSYCHOPHARMACOLOGY

Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated Patients

(2012) A. J. Mitchell et al.   SCHIZOPHRENIA BULLETIN

Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials

(2012) Jacqueline Caemmerer et al.   SCHIZOPHRENIA RESEARCH

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

(2012) Alkomiet Hasan et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2

(2012) G. S. Collins et al.   BMJ-British Medical Journal

Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review

(2012) Gavin P. Reynolds   Clinical Psychopharmacology and Neuroscience

A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)

(2011) T. Scott Stroup et al.   AMERICAN JOURNAL OF PSYCHIATRY

Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of Psychosis

(2011) Debra L. Foley et al.   ARCHIVES OF GENERAL PSYCHIATRY

Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents

(2011) Lawrence Maayan et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Assessment of Treatment Algorithms Including Amantadine, Metformin, and Zonisamide for the Prevention of Weight Gain With Olanzapine

(2011) Vicki Poole Hoffmann et al.   JOURNAL OF CLINICAL PSYCHIATRY

Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients

(2011) Po W. Wang et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications

(2011) T A P Lett et al.   MOLECULAR PSYCHIATRY

Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study

(2011) Maria Rosaria A. Muscatello et al.   SCHIZOPHRENIA RESEARCH

Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used

(2010) Alison Pope et al.   BRITISH JOURNAL OF PSYCHIATRY

Zonisamide-Induced Weight Loss in Schizophrenia

(2010) Jaewon Yang et al.   CLINICAL NEUROPHARMACOLOGY

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial

(2010) W. Wolfgang Fleischhacker et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Intentional Weight Loss in Overweight and Obese Patients With Severe Mental Illness

(2010) Richard I. G. Holt et al.   JOURNAL OF CLINICAL PSYCHIATRY

Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity

(2010) Evgueni Tchoukhine et al.   JOURNAL OF CLINICAL PSYCHIATRY

Topiramate Augmentation in Clozapine-Treated Patients With Schizophrenia

(2010) Margaret K. Hahn et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia

(2010) Deanna L. Kelly et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Topiramate dose effects on cognition: A randomized double-blind study

(2010) D. W. Loring et al.   NEUROLOGY

Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis

(2010) Lawrence Maayan et al.   NEUROPSYCHOPHARMACOLOGY

Behavioural Interventions for Obese Adults with Additional Risk Factors for Morbidity: Systematic Review of Effects on Behaviour, Weight and Disease Risk Factors

(2010) Stephan U. Dombrowski et al.   Obesity Facts

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

(2010) Christine Rummel-Kluge et al.   SCHIZOPHRENIA RESEARCH

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial

(2010) Preeta Kaur Narula et al.   SCHIZOPHRENIA RESEARCH

Prevalence of alcohol use disorders in schizophrenia - a systematic review and meta-analysis

(2009) J. Koskinen et al.   ACTA PSYCHIATRICA SCANDINAVICA

When Prevention Fails: Obesity Treatment Strategies

(2009) Louis J. Aronne et al.   AMERICAN JOURNAL OF MEDICINE

Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies

(2009) Alex J. Mitchell et al.   BRITISH JOURNAL OF PSYCHIATRY

Metformin for Obesity in Children and Adolescents: A Systematic Review

(2009) M. H. Park et al.   DIABETES CARE

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)

(2009) M. De Hert et al.   EUROPEAN PSYCHIATRY

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents

(2009) Christoph U. Correll   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity

(2009) Grigori Joffe et al.   JOURNAL OF CLINICAL PSYCHIATRY

Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?

(2009) Viktoria Simon et al.   JOURNAL OF CLINICAL PSYCHIATRY

Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients

(2009) David C. Henderson et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)

(2009) Jari Tiihonen et al.   LANCET

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

(2009)   LANCET

Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms

(2009) Gavin P Reynolds et al.   PHARMACOLOGY & THERAPEUTICS

Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial

(2009) Mario Álvarez-Jiménez et al.   SCHIZOPHRENIA RESEARCH

The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy

(2008) J. Wellmer et al.   ACTA NEUROLOGICA SCANDINAVICA

Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme

(2008) T. R. E. Barnes et al.   ACTA PSYCHIATRICA SCANDINAVICA

Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study

(2008) Ren-Rong Wu et al.   AMERICAN JOURNAL OF PSYCHIATRY

Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia

(2008) Olga O. Yevtushenko et al.   BRITISH JOURNAL OF PSYCHIATRY

General Cardiovascular Risk Profile for Use in Primary Care

(2008) Ralph B. D’Agostino et al.   CIRCULATION

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial

(2008) H Afshar et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats

(2008) S. Snigdha et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

(2008) René S Kahn et al.   LANCET

The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance

(2008) Kirsten Lykkegaard et al.   SCHIZOPHRENIA RESEARCH